Thursday 28 March 2013

Augmented Reality in Gaming and Entertainment









 
 
Reports Corner has added a latest report on "Augmented Reality in Gaming and Entertainment" to its database. Please visit https://www.reportscorner.com/reports/13395/Augmented-Reality-in-Gaming-and-Entertainment for further information about the report.


SYNOPSIS

Augmented Reality (AR) represents a live, direct or indirect, view of a physical, real-world environment whose elements are augmented by computer-generated sensory input, that enrich the user's perception of the real world.  AR has great potential of many industry verticals including:
• Education
• Healthcare
• Public Safety
• Manufacturing
• Energy Management
• Gaming and Entertainment
This research analyzes emerging AR applications in gaming and the general entertainment industry as a whole.  The first section of this report evaluates the development of the AR applications as a whole. The second section focuses on the use of AR in the entertainment industry.  It includes case studies and analysis on the use of AR applications gaming and the entertainment products and services vertical as a whole. The third section of the report provides analysis of the market for the AR applications in gaming with forecasting from 2013 through 2016.
REPORT BENIFITS

• Identify the drivers for AR as a whole
• Identify key growth opportunities in mobile augmented reality
• Understand the potential for AR in advertising and entertainment
• Recognize the advertising and marketing potential of AR applications
• Understand business models that will predominate as AR gains traction

TABLE OF CONTENTS
1.0          EXECUTIVE SUMMARY  4
2.0          INTRODUCTION                5
2.1          AUGMENTED REALITY EVOLUTION          6
2.2          AR APPLICATIONS DEVELOPMENT           6
2.3          AR IN INDUSTRY VERTICALS        7
2.3.1      GAMING             12
2.3.2      AR APPLICATIONS IN THE ENTERTAINMENT ARENA         12
2.3.3      AUGMENTED REALITY CHALLENGES        13
3.0          AR IN GAMING AND ENTERTAINMENT  16
3.1          CASE STUDY: INGRESS GAME     16
3.1.1      INGRESS ANALYSIS          16
3.1.2      INGRESS DISADVANTAGES          17
3.2          AR GAMING FOR PLAYSTATION                18
3.2.1      WONDERBOOK AR DEVICE FROM SONY 18
3.2.2      AR AND SECOND LIFE AVATAR   19
3.3          OPPORTUNITIES               19
3.3.1      THE USE OF AR APPLICATIONS IN ENTERTAINMENT         20
3.4          GOOGLE GLASSES POTENTIAL APPLICATIONS IN GAMING            24
3.4.1      INGRESS WITH GOOGLE GLASSES             28
3.5          STATISTICS AND COMPARISONS FOR AR APPLICATIONS IN ENTERTAINMENT      28
3.5.1      NOKIA AND ORANGE AR ADVERTISING CAMPAIGN         29
3.5.2      MACDONALD'S TRACKMYMACCA'S AR APP        30
3.5.3      HYUNDAI VIRTUAL TEST DRIVE  30
3.5.4      BBC FROZEN PLANT AR EVENT   31
3.5.5      ACCEPTANCE     31
4.0          MARKET FORECAST FOR AR IN GAMING AND ENTERTAINMENT 2013-2016           33
4.1          MARKET FORECAST 2013 TO 2018 AR IN GAMING             34
4.1.1      KEY INDICATORS              34
4.1.2      MARKET GROWTH INDICATORS                34
4.2          MARKET FORECAST BY REGION 34
4.2.1      WESTERN EUROPE           35
4.2.2      EASTERN EUROPE            35
4.2.3      MIDDLE EAST & AFRICA 35
4.2.4      LATIN & CENTRAL AMERICA        35
5.0          AR GAMES FORECASTS 2013-2016            37
5.1          AR GAMES IN ASIA & OCEANA   37
5.2          AR GAMES MARKET IN AUSTRALIA 2012-2016     37
5.3          AR GAMES IN CHINA 2011-2016 38
5.4          THE AR GAMES MARKET IN EUROPE 2011-2016  38
6.0          CONCLUSIONS  40
 

Sunday 24 March 2013

South Korea Wind Power Sector Analysis 2013

Reports Corner has added a latest report on "South Korea Wind Power Sector Analysis 2013" to its database. Please visit https://www.reportscorner.com/reports/13394/South-Korea-Wind-Power-Sector-Analysis-2013/ for further information about the report.


Wind Power in South Korea is being seen as the potential driver of renewable energy development in the country. Electricity generation through wind power has already progressed to significant levels and most of this has been developed onshore. The present onshore capacity installed in South Korea is at more than 480 MW by end of 2012, which is set to expand with many projects awaiting operational and constructional commencement.
The wind power sector in south Korea has been reformed which had stunted the growth a little bit but now with the reforms in place already, the capacity is growing and is expected to take the fast track to growth. To augment the rapid growth of wind energy in the country, the domestic heavy industries have taken upon themselves the onus of manufacturing the wind turbine generators that will reduce the sector’s dependence on imports and will also result in the reduction of wind energy production costs. The Feed in Tariff policy of the government has now been replaced by the Renewable Portfolio Standard. The research report points out to the various reasons behind this reform one of which was the low revenue given to wind generated electricity as compared to solar and hydro power.
Wind power in the offshore region in the country has immense potential owing to the expansive seas at its disposal and this has encouraged many companies to set up wind farms in the region. The private companies are investing huge resources in the process which will later on be retrieved through the high tariff of wind energy and the carbon credits they would receive as part of the renewable portfolio standard policy recently been introduced. Offshore wind is becoming the latest trend all over the world and South Korea is expected to become a major part of the vogue.
Given the problems cropping up with the onshore wind power development sector in the country, the South Korean offshore sector seems to be more lucrative as of now. Huge investments are being made in projects offshore and considering the expansive potential the country has in this sector, it will certainly attract the largest investment in the future and will be the key driver in developing the South Korea’s wind energy.
"South Korea Wind Power Sector Analysis 2013" research report discusses following aspect related to emerging wind power sector in South Korea:
Current Sector Trends
Onshore & Offshore Wind Potential
Wind Power Sector Indicators
Operating Wind Farms
Future Outlook & Sector Emerging Trends
Regulatory & Policy Framework
Competitive Landscape
Table of Contents


1. South Korea Wind Power Sector Landscape
2. Wind Power Resources
2.1 Onshore & Offshore Reserves
2.2 Onshore & Offshore Wind Map by Speed & Density
3. Wind Power Sector Indicators
3.1 Onshore
3.2 Offshore
4. Operating Wind Farms
4.1 Onshore Wind Farms
4.2 Offshore Wind Farms
5. Wind Power Feed In Tariff Structure
6. Wind Turbine Manufacturing
7. Emerging Trends
7.1 United Kingdom and South Korea Alliance for Offshore Wind Power
Development
7.2 Rising Investments from Government & Private Sector
7.3 Focus on Clean Energy to Drive Wind Power Installation
7.4 Development of World’s Largest Offshore Wind Farm
7.5 Super Sized Ships to Install Offshore Wind Turbines
7.6 South Korean Companies Developing Foreign Wind Farms
8. Wind Power Future Outlook
8.1 Onshore
8.2 Offshore
9. Regulatory & Policy Framework
9.1 Low Carbon, Green Growth Policy
9.2 Renewable Portfolio Standard Energy Policy
10. PEST Analysis
10.1 Political Analysis: Government Investments & Knowledge Sharing Policy
10.2 Economic Analysis: Low Cost Wind Power & Rising Energy Import Bill
10.3 Social Analysis: Increasing Social Acceptance
10.4 Technology Analysis: Transfer of Technology & International Collaborations
11. Competitive Landscape
11.1 Hyundai Heavy Industry
11.1.1 Business Overview
11.1.2 Turbine Portfolio
11.2 Samsung Heavy Industry
11.2.1 Business Overview
11.2.2 Turbine Portfolio
11.3 Daewoo, Shipbuilding & Marine Engineering
11.3.1 Business Overview
11.3.2 Turbine Portfolio
11.4 Doosan Heavy Industry and Construction
11.4.1 Business Overview
11.4.2 Turbine Portfolio
11.5 Unison
11.5.1 Business Overview
11.5.2 Turbine Portfolio
11.6 Vestas Wind Systems
11.6.1 Business Overview
11.6.2 Turbine Portfolio
11.7 Korea Electric Power Corporation
List Of Figures


Figure 1-1: Electricity Generation Capacity by Fuel, 2012
Figure 1-2: Share of Renewable Energy in Generation Capacity, 2012
Figure 1-3: Wind Power Capacity Growth in South Korea in Comparison to Asian during 2012
Figure 1-4: Share of Wind Power in Renewable Energy Capacity, 2012
Figure 1-5: On & Off Shore Wind Power Installed Capacity (MW), Feb’2013
Figure 1-6: Number of On & Off Shore Wind Turbines, Feb’2013
Figure 2-1: Onshore & Offshore Wind Reserves (GW)
Figure 2-2: Onshore & Offshore Wind Power Generation Potential (GWh)
Figure 2-3: Onshore Wind Power Potential by Province (GW)
Figure 2-4: Onshore Wind Power Generation Potential by Province (GWh)
Figure 2-5: Offshore Wind Power Potential by Province (GW)
Figure 2-6: Offshore Wind Power Generation Potential by Province (GWh)
Figure 2-7: Onshore Wind Speed Map at 60 Meters
Figure 2-8: Onshore Wind Density Map at 60 Meters
Figure 2-9: Onshore Wind Speed Map at 80 Meters
Figure 2-10: Onshore Wind Density Map at 80 Meters
Figure 2-11: Onshore Wind Speed Map at 100 Meters
Figure 2-12: Onshore Wind Density Map at 100 Meters
Figure 2-13: Onshore Wind Speed Map at 120 Meters
Figure 2-14: Onshore Wind Density Map at 120 Meters
Figure 2-15: Offshore Wind Speed Map at 80 Meters
Figure 2-16: Offshore Wind Density Map at 80 Meters
Figure 2-17: Offshore Wind Speed Map at 100 Meters
Figure 2-18: Offshore Wind Density Map at 100 Meters
Figure 2-19: Offshore Wind Speed Map at 120 Meters
Figure 2-20: Offshore Wind Density Map at 120 Meters
Figure 3-1: Wind Power Installed Capacity (MW), 2001-2012
Figure 3-2: Wind Power Installed Capacity Growth, 2001-2012
Figure 3-3: Wind Power Generation (GWh), 2000-2012
Figure 4-1: Wind Power Installed Capacity by Company (%), Feb’2013
Figure 4-2: Wind Power Installed Capacity by Company (MW), Feb’2013
Figure 4-3: Number of Wind Installed Turbine by Company, Feb’2013
Figure 5-1: Wind Power Tariff (KRW/kWh), 2010 & 2011
Figure 7-1: Renewable Energy Capacity Target (GW), 2012-2022
Figure 7-2: Wind Power Capacity Target (GW), 2030
Figure 8-1: 3rd Renewable Energy Supply Plan Targets for Wind Energy (GWh), 2015, 2020 & 2030
Figure 8-2: Wind Power Installed Capacity (MW), 2013-2018
Figure 8-3: Offshore Wind Power Installed Capacity Target (MW), 2013, 2016 & 2019
Figure 9-1: Renewable Portfolio Standards (RPS) Quota, 2012-2022

Saturday 23 March 2013

Construction sector in Bulgaria 2013

Reports Corner has added "Construction sector in Bulgaria 2013" to its latest reports offering. Please visit the link

(https://www.reportscorner.com/reports/13386/Construction-sector-in-Bulgaria-2013/ )
Synopsis

What projects are planned for the Bulgarian construction sector?
Report evaluates the competition, forecasts development to 2015.

Are commercial developers planning to invest in new office, service and retail spaces? What projects are planned for the public infrastructure segment of the market? Which companies are leading the way in terms of participation in the most significant upcoming investments? What is the outlook for manufacturers of building materials intended for use in Bulgaria?
Contractors and materials producers who are interested in a comprehensive view of the current activities and future prospects of this market will find that Construction sector in Bulgaria 2013, Development forecasts for 2013-2015 meets their needs and much more. This PMR publication provides data, analysis, competitive perspective and reliable forecasts for the residential, non-residential and civil engineering segments of the market, offering explanations of each unique characteristic – from the upcoming infrastructure projects of civil engineering to commercial and industrial plans for the non-residential segment.
This publication has been restructured to conform to additional PMR documents on construction markets in neighboring countries, making comparative analysis quick and simple. It provides deep analysis of trends influencing the current Bulgarian construction market and poised to affect development in the future, taking into account the country’s economic status and newsworthy events that are relevant to the construction industry.
This document provides an excellent analysis of the competitive environment of the construction market in Bulgaria that includes comprehensive information on the country’s leading companies, the projects they have recently completed and plan to take part in and their strategies moving forward. It contains updates on merger and acquisition activity and commentary from PMR experts with years of experience in observing and analysing this particular market, plus an index of the 100 leading contractors active in Bulgaria and an Excel database of 100 of the most promising projects still in the planning stages.
Precise and accurate forecasts for the period 2013-2015 are enhanced by analytical coverage of the regulatory actions, plans for governmental development programmes and financial and investment developments that will influence new projects and the direction of market expansion.
Readers will discover which of the market’s main segments is expand to experience the greatest degree of growth, how prices have evolved in recent months and which building materials producers have gained the strongest positions within the marketplace. They will learn the details of plans for infrastructure expansion and the common methods of financing transport infrastructure construction in Bulgaria, and discover the projected total of newly constructed housing units expected to be ready for market by 2015.
This report provides informational support for construction industry professionals and specialists in finance, design and project management, consulting, research, and industry analysis in performing a wide variety of tasks, from market assessment to M&A activity to new business development and report preparation – quickly and accurately.
Table of Contents  I. Methodology p. 7

II. Executive summary p. 9

III. Macroeconomic overview p. 13

IV. Construction overview p. 27

V. Civil engineering construction p. 39

VI. Non-residential construction p. 53

VII. Residential construction p. 65

VIII. Competitive environment p. 77

IX. List of graphs p. 85

X. List of tables p. 87

XI. About PMR p. 89

Cost of Power Generation - Renewables Compete with Conventional Alternatives as the Levelized Cost of Electricity (LCOE) is driven down by Technological Developments and Mass Deployments



 
 
 
 
Reports Corner has added “Cost of Power Generation - Renewables Compete with Conventional Alternatives as the Levelized Cost of Electricity (LCOE) is driven down by Technological Developments and Mass Deployments" to its latest reports offering. Please visit the link (https://www.reportscorner.com/reports/13393/Cost-of-Power-Generation---Renewables-Compete-with-Conventional-Alternatives-as-the-Levelized-Cost-of-Electricity-(LCOE)-is-driven-down-by-Technological-Developments-and-Mass-Deployments)

Summary
GBI Research, a leading business intelligence provider, has released its latest research, "Cost of Power Generation - Renewables Compete with Conventional Alternatives as the Levelized Cost of Electricity (LCOE) is driven down by Technological Developments and Mass Deployments". This report gives an in-depth analysis of the cost of power generation, levelized cost of electricity for different power generating technologies, both renewable and conventional, in six major countries like the US, China, India, Germany, the UK and Australia between 2011 and 2020. The report also provides information on key trends, factors impacting the cost of power generation and electricity prices.

Scope
- Levelized cost of electricity for power generation from renewable resources such as biomass, wind and solar PV from 2011 to 2020

- Levelized cost of electricity for power generation from conventional resource such as from coal and gas from 2011 to 2020

- Key trends of cost of power generation in global power market

- Factors impacting cost of power generation and electricity prices

- Overview of grid parity

Reasons to buy

- Identify the challenges associated with the market to take up necessary actions to transform them into opportunities for future growth
- Understand and respond to the trends of the market to formulate strategies accordingly

- Identify the scope of different technologies and investment opportunities of the markets globally
- Make better-informed business decisions armed with hard-to-get LCOE data in six major countries

 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 11
3 Levelized Cost of Energy 12
3.1 Levelized Cost of Energy, Overview 12
3.2 Retail Cost, Levelized Cost of Electricity and Grid Parity 13
3.3 Components of Cost of Power Generation 15
3.3.1 Overnight Capital Cost 16
3.3.2 Fuel Cost 17
3.3.3 Operations and Maintenance Costs 17
3.3.4 Financing Cost 17
3.3.5 Capacity Factor 18
3.3.6 Discount Rates 18
4 Factors Impacting the Cost of Power Generation 19
4.1 Technology Learning Effect 19
4.2 CO2 Lifecycle Emissions and the Cost Price 19
4.2.1 Lifecycle Greenhouse Gas Emissions 19
4.2.2 Global Initiatives to Reduce Carbon Footprint 21
4.2.3 Evolution of Carbon Trading Market 22
4.2.4 Emission Trading 23
4.3 Capacity Factor 24
4.4 Fuel Prices 24
5 Factors Impacting Electricity Prices 25
5.1 Structural Costs 25
5.2 Cost of Carbon 25
5.3 Grid Extension 26
5.4 Tariff Subsidies 26
5.5 Fuel Subsidies 26
6 Levelized Cost of Electricity, Market Dynamics 27
6.1 Key Trends 27
6.1.1 LCOE for Solar PV to Decline at a Significant Rate during Forecast Period 27
6.1.2 Fluctuating Fuel Costs and Increasing Capital Costs of Conventional Technologies are Enhancing the ompetitiveness of Renewable Technologies 28
6.1.3 Grid Parity is Becoming a Reality 28
7 Power Market Scenario in Major Countries, 2012–2020 29
7.1 Power Market, Global, Cumulative Installed Capacity, 2012–2020 29
7.2 Power Market, the US, Cumulative Installed Capacity and Levelized Cost of Electricity, 2012–2020 31
7.2.1 Power Market, the US, Cumulative Installed Capacity, by Technology, 2012–2020 31
7.2.2 Power Market, the US, Levelized Cost of Electricity, by Technology, 2012–2020 33
7.3 Power Market, China, Cumulative Installed Capacity and Levelized Cost of Electricity, 2012–2020 34
7.3.1 Power Market, China, Cumulative Installed Capacity, by Technology, 2012–2020 34
7.3.2 Power Market, China, Levelized Cost of Electricity, by Technology, 2012–2020 36
7.4 Power Market, India, Cumulative Installed Capacity and Levelized Cost of Electricity, 2012–2020 37
7.4.1 Power Market, India, Cumulative Installed Capacity, By Technology, 2012–2020 37
7.4.2 Power Market, India, Levelized Cost of Electricity, by Technology, 2012–2020 39
7.5 Power Market, Germany, Cumulative Installed Capacity and Levelized Cost of Electricity, 2012–2020 40
7.5.1 Power Market, Germany, Cumulative Installed Capacity, by Technology, 2012–2020 40
7.5.2 Power Market, Germany, Levelized Cost of Electricity, by Technology, 2012–2020 42
7.6 Power Market, the UK, Cumulative Installed Capacity and Levelized Cost of Electricity, 2012–2020 43
7.6.1 Power Market, the UK, Cumulative Installed Capacity, by Technology, 2012–2020 43
7.6.2 Power Market, the UK, Levelized Cost of Electricity, by Technology, 2012–2020 44
7.7 Power Market, Australia, Cumulative Installed Capacity and Levelized Cost of Electricity, 2012–2020 45
7.7.1 Power Market, Australia, Cumulative Installed Capacity, by Technology, 2012–2020 45
7.7.2 Power Market, Australia, Levelized Cost of Electricity, by Technology, 2012–2020 47
8 Power Market, Cost of Power Generation, Comparative Analysis in Major Countries 48
8.1 Power Market, Levelized Cost of Electricity Range, Comparative Analysis, By Technology, 2012 48
8.1.1 Power Market, the US, Levelized Cost of Electricity Range, by Technology, 2012 48
8.1.2 Power Market, China, Levelized Cost of Electricity Comparison, by Technology 49
8.1.3 Power Market, India, Levelized Cost of Electricity Range, by Technology, 2012 50
8.1.4 Power Market, Germany, Levelized Cost of Electricity Range, by Technology, 2012 51
8.1.5 Power Market, the UK, Levelized Cost of Electricity Range, by Technology, 2012 52
8.1.6 Power Market, Australia, Levelized Cost of Electricity Range ($/kWh), By Technology, 2012 53
8.2 Renewable Power Market, Levelized Cost of Electricity, by Country, 2012 54
8.2.1 Biomass Power Market, Global, Levelized Cost of Electricity in Major Countries 54
8.2.2 Solar PV Power Market, Global, Levelized Cost of Electricity in Major Countries, 2011–2020 61
8.2.3 Wind Power Market, Global, Levelized Cost of Electricity in Major Countries, 2011–2020 69
8.3 Thermal Power Market, Levelized Cost of Electricity, by Country, 2012 77
8.3.1 Coal-fired Power Market, Global, Levelized Cost of Electricity in Major Countries, 2011–2020 77
8.3.2 Gas-fired Power Market, Global, Levelized Cost of Electricity in Major Countries, 2011–2020 84
9 Appendix 91
9.1 Market Definition 91
9.1.1 Technologies Covered 91
9.1.2 Geographies Covered 91
9.1.3 Major Definitions 91
9.2 Assumptions 92
9.3 Abbreviations 92
9.4 References 93
9.5 Methodology 93
9.5.1 Coverage 93
9.5.2 Secondary Research 94
9.5.3 Primary Research 94
9.5.4 Expert Panel Validation 94
9.6 Contact Us 95
9.7 Disclaimer 95
 
 

China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth



Reports Corner has added “China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth" to its latest reports offering. Please visit the link (https://www.reportscorner.com/reports/13392/China-Pharmaceutical-Market-Outlook---Government-Incentives,-Healthcare-Reform-and-a-Rapidly-Ageing-Population-Provide-Strong-Stimulus-for-Growth)

Summary
GBI Research’s new report: "China Pharmaceutical Market Outlook - Government Incentives, Healthcare Reform and a Rapidly Ageing Population Provide Strong Stimulus for Growth" provides in-depth analysis of the trends, issues and challenges facing the Chinese pharmaceutical market. It details the macroeconomic environment of China, providing a background of the financial and demographic situations in the country, as well as identifying key demographics. It covers the pharmaceutical market broken down by market segment, and the popularity of biosimilars and biologics, identifying where the strongest market potentials lie. It includes information on the regulatory guidelines for the manufacture, development and distribution of pharmaceuticals. The report also covers information on the competitive landscape in the Chinese pharmaceutical market, identifying market leaders and key trends in investment. It also includes the key drivers and barriers of the pharmaceutical market in more detail. It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

China is currently one of the most important markets in the pharmaceutical industry. It is the most populous country in the world, with a recorded population of over 1.34 billion as of 2011. The country has the second-largest economy after the US with a GDP of $7.3 trillion as of 2011, and its economy is one of the fastest growing in the world, with average growth of 10.6% over the last decade (World Bank, 2012). China is the world’s largest exporter and second-largest importer of goods.

In 2011, China overtook Germany to become the third largest pharmaceutical market in the world, and is predicted to overtake Japan by 2015 to become the second largest. In 2011, its estimated value was approximately $64 billion. The size of China’s pharmaceutical market is primarily a result of its large population rather than its maturity, as it is still an emerging market. The Chinese pharmaceutical market has the world’s largest manufacturing capabilities, producing more than 4,500 drugs and exporting various pharmaceutical products such as acetylsalicylic acid and metamizole to the global market. Recent healthcare reforms have been driving the pharmaceutical market by increasing public access to drugs. In addition, recent population changes such as a majority move from rural to urban China, a rapidly aging community and an increasing overweight population are driving the value of the Chinese pharmaceutical market.

Scope
The report analyzes the Chinese pharmaceutical market, looking at -

- Macroeconomic analysis of China covering economic, demographic and market-specific indicators

- Market analysis of segments such as branded and generic drugs, prescribed and OTC drugs, and biopharmaceuticals
- Industry landscape, looking at pharmaceutical pricing policies, supply chain, drug regulations and healthcare reforms

- Competitive profiling of major domestic and international companies operating in the Chinese pharmaceutical market in addition to the important M&A deals in recent years

- Drivers and barriers of the Chinese pharmaceutical market

Reasons to buy
The report will enhance your decision-making capability by allowing you to -

- Develop market-entry and market-expansion strategies by identifying the leading segments poised for strong growth
- Devise a more tailored country strategy through understanding key drivers of and barriers to the pharmaceutical market

- Develop key strategic initiatives by understanding leading companies’ key focus areas
- Accelerate and strengthen your market position by identifying key companies for M&A and strategic partnerships

 Table of Contents
1 Table of Contents 5
1.1 List of Tables 6
1.2 List of Figures 7
2 China Pharmaceutical Market Outlook – Introduction 8
3 China Pharmaceutical Market Outlook – Macroeconomic Analysis 9
3.1 General Economics 9
3.1.1 Gross Domestic Product 9
3.1.2 Inflation 11
3.1.3 Exchange Rate 12
3.1.4 Trade Balance 13
3.1.5 Foreign Direct Investment 17
3.2 Demographic 18
3.2.1 Population Size 18
3.2.2 Population Distribution 20
3.3 Health and Healthcare 22
3.3.1 Healthcare Expenditure 22
3.3.2 Public and Private Expenditure 25
3.3.3 Healthcare Facilities 27
3.3.4 Immunization 29
3.3.5 Smoking and Alcohol Use Prevalence 30
3.3.6 Obesity 32
3.3.7 Life Expectancy 33
3.3.8 Leading Causes of Death 34
4 China Pharmaceutical Market Outlook – Market Segments 35
4.1 Branded and Generic Drugs 35
4.2 Over-the-Counter and Prescription Drugs 39
4.3 Biopharmaceuticals 42
5 China Pharmaceutical Market Outlook – Industry Characteristics 44
5.1 Pricing Policy 44
5.2 Regulatory Landscape 45
5.2.1 Drug Manufacturing Regulations 46
5.2.2 New Drug Approval 46
5.2.3 Intellectual Property Protection 47
5.2.4 Advertising 47
5.3 Healthcare Overview 48
5.3.1 Healthcare Reform 48
5.3.2 Insurance and Reimbursement 49
5.4 Pharmaceutical Supply Chain 50
6 China Pharmaceutical Market Outlook – Competitive Landscape 51
6.1 Domestic Companies in China 51
6.1.1 Sinopharm 51
6.1.2 Shanghai Pharmaceutical 52
6.1.3 Jointown Pharmaceutical 52
6.1.4 Nanjing Pharmaceutical 53
6.1.5 Harbin Pharmaceutical 53
6.2 Macroscopic Domestic Deals Overview 54
6.3 Foreign Companies in China 56
7 China Pharmaceutical Market Outlook – Market Drivers and Barriers 57
7.1 Drivers 57
7.1.1 Increasing Overweight and Obese Population 57
7.1.2 High Smoking Prevalence 57
7.1.3 Aging Population 58
7.1.4 Government Financial Support 58
7.1.5 Healthcare Reforms 58
7.1.6 Increasing Urbanization 59
7.2 Barriers 59
7.2.1 Poor Drug Quality 59
7.2.2 Competition from Neighboring Countries 59
7.2.3 Popularity of TCM 59
7.2.4 Increasing Labor Costs 60
7.2.5 Poor Intellectual Property Protection 60
8 China Pharmaceutical Market Outlook – Appendix 61
8.1 Market Definitions 61
8.2 Abbreviations 61
8.3 Bibliography 62
8.4 Research Methodology 64
8.4.1 Coverage 64
8.4.2 Secondary Research 64
8.4.3 Primary Research 64
8.4.4 Expert Panel Validation 65
8.5 Contact Us 65
8.6 Disclaimer 65
 

Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson’s disease treatment will boost market despite patent cliff



 
Reports Corner has added “Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson’s disease treatment will boost market despite patent cliff" to its latest reports offering. Please visit the link (https://www.reportscorner.com/reports/13391/Neurodegenerative-Diseases-Market-to-2018---New-product-entries-in-both-niche-and-broader-Parkinson’s-disease-treatment-will-boost-market-despite-patent-cliff)

Summary
GBI Research, the leading business intelligence provider, has released its latest research "Neurodegenerative Diseases Market to 2018 - New product entries in both niche and broader Parkinson’s disease treatment will boost market despite patent cliff". A highly dynamic market scenario is expected in Neurodegenerative diseases in the next few years, with a number of patent expiries and anticipated new drug approvals. The market for Alzheimer’s disease has not seen any recent major breakthroughs, and is expected to experience a decline due to the patent expiry of several major products. The market for Parkinson’s disease, on the other hand, is expected to experience growth due to the anticipated approval of expensive products such as Duodopa in the US, in spite of the fact that it will soon hit its own patent cliff. Additionally, the overall aging of populations the developed world is expected to increase the number of patients suffering from these diseases due to their relatively high prevalence in the elderly.

Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, and key M&A and licensing deal trends in Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Amyotrophic Lateral Sclerosis (ALS) and Huntington’s Disease (HD).
- The current therapeutic environment in the treatment of AD, PD, HD and ALS across the top seven developed markets, including the US, Germany, France, the UK, Italy, Spain and Japan.

- Market data on the geographical landscape and therapeutic landscape, including market size, annual cost of therapy, treatment usage patterns such as disease population and prescription populations.

- Market forecasts for all four indications across the US, the top five countries in Europe (EU5) - Germany, France, the UK, Italy, and Spain- as well as Japan.
- Key market drivers and barriers

- The major deals that have taken place in the Neurodegenerative Diseases Market in recent years. Coverage includes Mergers and Acquisitions (M&As) as well as co-development and licensing agreements, which are segmented on the basis of geography and total value. A concomitant analysis of the licensing deal values for products by molecule types and is also provided.

Reasons to buy
The report will assist business development and marketing executives to strategize their product launches, by allowing them to -

- Understand the competitive environment for Neurodegenerative Diseases
- Understand the clinical and commercial impact of major patent expiries in the neurodegenerative diseases markets
- Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the neurodegenerative diseases market in the forecast period
- Grasp the unmet need which exists in the neurodegenerative diseases Market
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps

Table of Contents
1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Neurodegenerative Diseases Market to 2018: Introduction 13
3 Neurodegenerative Diseases Market to 2018: Global Market Overview 14
3.1 Revenue 14
3.2 Treatment Usage Pattern 16
3.3 Distribution by Market 17
3.4 Drivers and Restraints of the Neurodegenerative Diseases Market 18
3.4.1 Drivers 18
3.4.2 Restraints 18
4 Therapeutic Landscape 19
4.1 Market for Alzheimer’s Disease 19
4.1.1 Introduction 19
4.1.2 Revenue and Forecasts 21
4.1.3 Treatment Usage Pattern 23
4.1.4 Geographical Landscape 24
4.1.5 Drivers and Restraints for the Alzheimer’s Disease Market 46
4.2 Market for Parkinson’s Disease 47
4.2.1 Introduction 47
4.2.2 Revenue and Forecasts 49
4.2.3 Treatment Usage Pattern 50
4.2.4 Geographical Landscape 51
4.2.5 Drivers and Restraints for the Parkinson’s Disease Market 73
4.3 Market for Amyotrophic Lateral Sclerosis 74
4.3.1 Introduction 74
4.3.2 Revenue and Forecasts 76
4.3.3 Treatment Usage Pattern 77
4.3.4 Geographical Landscape 78
4.3.5 Drivers and Restraints for the Amyotrophic Lateral Sclerosis Market 100
4.4 Market for Huntington’s Disease 101
4.4.1 Introduction 101
4.4.2 Revenue and Forecasts 103
4.4.3 Treatment Usage Pattern 104
4.4.4 Geographical Landscape 105
4.4.5 Drivers and Restraints for the Huntington’s Disease Market 127
5 Neurodegenerative Diseases Market: Pipeline Analysis 128
5.1 Introduction 128
5.2 Summary of the Current Neurodegenerative Diseases R&D Pipeline 129
5.2.1 Alzheimer's Disease 129
5.2.2 Amyotrophic Lateral Sclerosis 142
5.2.3 Parkinson’s Disease 147
5.2.4 Huntington’s Disease 155
6 Neurodegenerative Diseases Market: Deals and Strategic Consolidations 158
6.1 Merger and Acquisition Deals 158
6.1.1 Sanofi-Synthelabo Merges with Aventis 160
6.1.2 Bayer Acquires Schering 160
6.1.3 Takeda Pharma Completes Acquisition of Nycomed International for $13,681m 160
6.1.4 Teva Pharma Acquires Ivax 160
6.1.5 Abbott Labs Acquires Solvay Pharma 160
6.1.6 Teva Completes Acquisition of Cephalon for $6.8 billion 160
6.1.7 UCB Acquires 87.62% Stake in Schwarz Pharma 161
6.1.8 Biovail Acquires Valeant Pharma 161
6.1.9 Dainippon Sumitomo Pharma Completes Acquisition of Sepracor for $2.6 Billion 161
6.1.10 Merck Acquires Banyu Pharma 161
6.1.11 Amgen Completes Acquisition of Micromet for $1.2 Billion 161
6.1.12 Bayer Acquires Minority Stake in Bayer Schering Pharma 161
6.1.13 Daiichi Sankyo Completes Acquisition of Plexxikon 162
6.1.14 Lundbeck Acquires Ovation Pharma 162
6.1.15 Eli Lilly and Company Acquires Avid RadioPharma 162
6.1.16 Abbott Labs Completes Acquisition of Facet Biotech 162
6.1.17 Biogen Idec Acquires Fumapharm 162
6.1.18 Upsher-Smith Completes Acquisition of Remaining 84% Stake in Proximagen for up to $555m 163
6.1.19 Sun Pharma Acquires Controlling Stake in Taro Pharma 163
6.1.20 Pfizer Acquires Rinat Neuroscience 163
6.1.21 Cubist Pharma Completes Acquisition of Adolor for $415m 163
6.1.22 Biogen Idec Acquires Panima Pharma 164
6.1.23 Teva Pharma Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey 164
6.1.24 Fujifilm Holdings Acquires 66% Stake in Toyama Chemical 164
6.1.25 MGI PHARMA Acquires Guilford Pharma 164
6.1.26 H. Lundbeck Acquires LifeHealth 164
6.1.27 Endo Pharma Completes Acquisition of Penwest Pharma 165
6.1.28 EPIX Pharma Acquires Predix Pharma 165
6.1.29 Biogen Idec Acquires Syntonix Pharmaceuticals 165
6.1.30 Biotie Therapies Acquires Synosia Therapeutics 165
6.2 Licensing Agreements 166
6.2.1 Cephalon Enters into a Licensing Agreement with Mesoblast for Regenerative Medicine 167
6.2.2 Idera Pharma Enters into a Licensing Agreement with Merck 167
6.2.3 Astellas Pharma Enters into Licensing Agreement with CoMentis for Beta-Secretase Inhibitors 167
6.2.4 Synosia Therapeutics Enters into Licensing Agreement with UCB for SYN-115 and SYN-118 167
6.2.5 GlaxoSmithKline Signs an Agreement with AFFiRiS 168
6.2.6 Biogen Enters into an Agreement with Acorda Therapeutics 168
6.2.7 BioMS Medical Enters into Licensing Agreement with Eli Lilly 168
6.2.8 AC Immune Enters into Licensing Agreement with Genentech for Anti-Tau Antibodies 168
6.2.9 Biovail Enters into Licensing Agreement with Acadia Pharmaceuticals 168
6.2.10 Biogen Idec Enters into Licensing Agreement with Knopp Neurosciences for KNS-760704 169
6.2.11 AstraZeneca Enters into Licensing Agreement with Targacept 169
6.2.12 AC Immune Enters into Licensing Agreement with Genentech 169
6.2.13 Proximagen Enters into Licensing Agreement with Upsher-Smith Labs 169
6.2.14 Merck Serono Enters into Licensing Agreement with Apitope Technology 170
6.2.15 Serono Enters into Licensing Agreement with Newron Pharma for Safinamide 170
6.2.16 Shire Exercises Option to License Adenosine A2A from Heptares Therapeutics 170
6.2.17 GlaxoSmithKline Enters into Licensing Agreement with Impax Pharma for IPX066 170
6.2.18 Santhera Pharmaceuticals Enters into Licensing Agreement with Ipsen for Fipamezole 171
6.2.19 Domain Therapeutics Enters into Licensing Agreement with Merck Serono 171
6.2.20 Addex Pharma Enters into Collaboration and Licensing Agreement with Merck & Co 171
6.2.21 Curis Enters into Licensing Agreement with Wyeth Pharma 171
6.2.22 Pfizer Enters into a License and Collaboration Agreement with Transtech Pharma 171
6.2.23 Antisense Therapeutics Enters into Licensing Agreement with Teva Pharma 172
6.2.24 Biogen Idec Enters into Licensing Agreement with Vernalis 172
6.3 Co-Development Deals 173
6.3.1 GlaxoSmithKline Signs an Agreement with Targacept 174
6.3.2 GlaxoSmithKline Enters into an Agreement with EPIX Pharma 174
6.3.3 Evotec Enters into Co-Development Agreement with Roche 174
6.3.4 Pfizer Enters into Co-Development Agreement with Medivation for Dimebon 174
6.3.5 Alectos Therapeutics Enters into Research Collaboration with Merck & Co 174
6.3.6 Targacept Expands its Collaboration Agreement with AstraZeneca 175
6.3.7 Boehringer Ingelheim Partners with Vitae Pharma 175
6.3.8 Elan Enters into Co-Development Agreement with Transition Therapeutics 175
6.3.9 Ceregene Enters into Agreement with Genzyme 175
7 Appendix 176
7.1 Market Definitions 176
7.2 Abbreviations 176
7.3 Sources 177
7.4 Research Methodology 179
7.4.1 Coverage 180
7.4.2 Secondary Research 180
7.4.3 Primary Research 180
7.5 Therapeutic Landscape 181
7.5.1 Epidemiology-based Forecasting 181
7.5.2 Market Size by Geography 182
7.6 Geographical Landscape 183
7.7 Pipeline Analysis 184
7.8 Competitive Landscape 184
7.8.1 Expert Panel Validation 184
7.9 Contact Us 184
7.10 Disclaimer 184